Bookmark and Share

GI SPORE: Publications

Progress Report Publication List (2009 – 2012)

Last updated January, 2012

(Names in bold = SPORE project investigators; * = Biostatistical and Informatics Core)

Project 1 (Renewal)

Carcinogenic Metals, Colorectal Neoplasia Risk and Progression in Appalachia 

  1. Johnson N, Shelton BJ*, Hopenhayn C, Tucker TT, Unrine JM, Huang B, Christian W, Zhang Z, Shi X, Li L. Concentrations of arsenic, chromium, and nickel in toenail samples from Appalachian Kentucky residents. J Environ Pathol Toxicol Oncol 30:213-23, 2011.
  2. Zhang Z, Wang X, Cheng S, Sun L, Son YO, Yao H, Li W, Budhraja A, Li L, Shelton BJ*, Tucker T, Arnold SM, Shi X. Reactive oxygen species mediate arsenic induced cell transformation and tumorigenesis through Wnt/β-catenin pathway in human colorectal adenocarcinoma DLD1 cells. Toxicol Appl Pharmacol 256:114-21, 2011.

Project 2 (P20 Funding)

Hepatitis C and Tumor Suppressors in Hepatocellular Carcinoma 

Peer-reviewed Original Research 

  1. McGivern DR, Villanueva RA, Chinnaswamy S, Kao CC, Lemon SM. Impaired replication of hepatitis C virus containing mutations in a conserved NS5B retinoblastoma protein-binding motif. J Virol 83:7422-33, 2009. PMCID: PMC2708619
  2. Liang Y, Shilagard SY, Xiao N, Snyder DT, Lau L, Cicalese H, Weiss H*, Vargas G, Lemon SM. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137:1448-58, 2009.
  3. Villanueva RA, Jangra RK, Yi MK, Pyles R, Bourne N, Lemon SM. miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Antiviral Research 88:119-23, 2010.
  4. Jangra R, Yi M, Lemon SM. miR-122 regulation of hepatitis C virus translation and infectious virus production. J Virol 84:6615-25, 2010. PMCID: PMC2903297
  5. Jangra R, Yi M, Lemon SM. DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not IRES-directed translation. J Virol 84:6810-24, 2010. PMCID: PMC2903299
  6. Kannan RP, Hensley LL, Evers LE, Lemon SM, McGivern DR. Hepatitis C virus causes cell cycle arrest at the level of entry to mitosis. J Virol 85:7989-8001, 2011. PMCID: PMC 3147967
  7. Lemon SM and McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology, 2012. (in press).
  8. Shimakami T, Yamane D, Jangra RK, Kempf BJ, Spaniel C, Barton DJ, Lemon SM. Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex. Proc Natl Acad Sci USA, 2012. (in press).


  1. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 30:1969-83, 2011.

Book Chapters 

  1. Lanford RE, Lemon SM and Walker C. The chimpanzee model of hepatitis C infections and small animal surrogates. Hepatitis C Antiviral Drug Discovery & Development. Y. He and T. Tan (eds). Horizons Scientific Press, Norwich. 2010, pp 99-132.
  2. McGivern DR and Lemon SM. Epigenetic changes in hepatitis C virus-associated hepatocellular carcinoma. In: X.W. Wang, J. Grisham, and S. Thorgeirssen (eds.) Molecular Genetics of Liver Neoplasia, Springer, New York. 2011, pp 129-146.
  3. Fried MW, Darling MW and Lemon SM. Hepatitis C. In: E.R. Schiff, M.F. Sorrell, and W.C. Maddrey. (eds) Schiff’s Diseases of the Liver, Wiley-Blackwell, Oxford. In press. 2011.

Project 3 (Renewal)

Targeting WNT Signaling in Colorectal Cancers with Novel Derivatives of Natural Products 

  1. Yu T, Chen X, Zhang W, Colon D, Shi J, Napier D, Rychahou P, Lu W, Lee EY†, Weiss HL*, Evers BM, Liu C. Regulation of the potential marker for intestinal cells, Bmi1, by beta-catenin and the zinc finger protein KLF4: Implications for colon cancer. J Biol Chem, 2012. (in press).

Project 4 (P20 Funding)

Targeted Inhibition of PI3K Pathway Components as Novel Treatment of Colorectal Cancers 

A. Primary Publications from P20 CA150343 

  1. Liu J, Weiss HL*, Rychahou PG, Jackson LJ, Evers BM, Gao T. Loss of PHLPP expression in colon cancer: Role in proliferation and tumorigenesis. Oncogene 28:994-1004, 2009. PMCID: PMC2921630
  2. Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, Gao T, Evers BM. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res 29:3185-3190, 2009. PMCID: PMC2901158
  3. Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhou Y, Rychahou PG, Evers BM. PTEN loss induces epithelial-mesenchymal transition in human colon cancer. Anticancer Res 11:4439-4449, 2009. PMCID: PMC2932708
  4. Gulhati P, Cai Q, Li J, Liu J, Rychahou P, Qiu S, Lee E†, Silva SR, Bowen KA, Gao T, Evers BM. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 15:7207-7216, 2009. PMCID: PMC2898570
  5. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL*, Evers BM. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210:767-76, 776-8, 2010. PMCID: PMC2895913
  6. Larson Y, Liu J, Stevens PD, Li X, Li J, Evers BM, Gao T. Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J Biol Chem 285:24987-98, 2010. PMCID: PMC2915734
  7. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 30:4951-8, 2010. PMCID: PMC3141822
  8. Lin J, Stevens PD, Gao T. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem 286:6510-20, 2011. PMCID: PMC3057781
  9. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY†, Weiss HL*, O’Connor KL, Gao T, Evers BM. mTORC1 and mTORC2 regulate EMT, motility and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71:3246-56, 2011. PMCID: PMC3085654
  10. Zaytseva Y, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Letters, 2012. (in press).
  11. Guo Z, Zhou Y, Evers BM, Wang Q. Rictor regulates FBXW7-dependent c-Myc and cylcin E degradation in colorectal cancer cells. Biochem Biophys Res Commun, 2012. (in press).
  12. Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor KL, Morris AJ, Sunkara M, Weiss HL*, Lee EY†, Evers BM. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res, 2012. (in press).

B. Collaborative Publications as a result of funding from P20 CA150343 (supplied key reagents, technical/intellectual expertise and/or critical animal models) 

  1. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-?B is required for inflammation-induced cell migration and invasion. Cancer Cell 15:416-428, 2009. PMCID: PMC2881229
  2. Lee G, Goretsky T, Managlia E, Dirisina R, Singh AP, Brown JB, May R, Yang GY, Ragheb JW, Evers BM, Weber CR, Turner JR, He XC, Katzman RB, Li L, Barrett TA. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139:869-81, 2010. PMCID: PMC2930080
  3. Espejo R, Rengifo-Cam W, Schaller M, Evers BM, Sastry S. PTP-PEST controls motility, adherens junction assembly and Rho GPase activity in colon cancer cells. Am J Physiol Cell Physiol 299:C454-63, 2011. PMCID: PMC2928632
  4. Zhang W, Sviripa V, Kril LM, Chen X, Yu T, Shi J, Rychahou P, Evers BM, Watt DS, Liu C. Fluorinated n,n-dialkylaminostilbenes for Wnt pathway inhibition and colon cancer repression. J Med Chem 54:1288-97, 2011. PMCID: PMC3073490
  5. Tammali R, Reddy AB, Saxena A, Rychahou PG, Evers BM, Qiu S, Awasthi S, Ramama KV, Srivastava SK. Inhibition of aldose reductase prevents colon cancer metastasis. Carcinogenesis 32:1259-67, 2011. PMC Journal – In Process.
Page last updated: 9/30/2013 3:48:50 PM